Several factors play a role in the risk of osteoarthritis (OA), including age, sex, genetics, ethnicity, behavioral influences, obesity, and occupation (1). In addition, epidemiologic studies in women suggest that estrogen loss may be accompanied by an increase in the prevalence and incidence of knee and hip OA (2), which may help explain the sex differences in the prevalence of OA.
A genetic contribution to OA has been suggested in several epidemiologic studies (3). Twin studies, segregation analyses, linkage analyses, and candidate gene association studies have generated important information about inheritance patterns and the location in the genome of potentially causative mutations, although results across studies are, to date, inconsistent. Linkage and family studies have suggested that both sex-specific and anatomic site–specific genes are likely to influence an individual's risk of developing OA (3, 4).
In recent years, there has been considerable success in identifying genes that are involved in susceptibility to primary OA. In the current study, we focused on 5 genes: ASPN, CALM1, COL2A1, COMP, and FRZB. FRZB codes for secreted Frizzled-related protein 3, an antagonist of Wnt signaling. Wnt/β-catenin signaling regulates chondrocyte phenotype, maturation, and function (5). Through its influence on Wnt signaling, FRZB is a powerful and direct modulator of chondrocyte maturation (6). Accelerated cartilage breakdown has been shown to develop in knockout mice deficient in this gene (7). The original study in which an association of FRZB with hip OA was reported involved a cohort of women (8); that study showed that the associated alleles at FRZB reduced the activity of the protein encoded. In particular, the haplotype composed of substitutions at 2 highly conserved aspartic acid residues in FRZB (R200W and R324G) was highlighted as a strong risk factor for primary hip OA. A role for the same alleles/haplotypes in generalized radiographic OA (9) and in hip OA (10) has been reported in other studies in Caucasian populations. Evidence for a differential association of the FRZB R200W single-nucleotide polymorphism (SNP) with hip OA and osteoporosis has been reported (11).
Asporin is a member of the leucin-rich repeat (LRR) proteins, a series of noncollagenous glycoproteins that contribute to the regulation of tissue assembly and properties (12). Like similar LRRs such as decorin and biglycan, asporin binds to transforming growth factor (TGF). In particular, asporin suppresses TGFβ-mediated expression of the genes encoding 2 cartilage structural component genes, aggrecan and type II collagen, and reduces proteoglycan accumulation in an in vitro model of chondrogenesis. Kizawa and coworkers (13) reported significant association between a polymorphism in the aspartic acid (D) repeat in the asporin-encoding gene (ASPN) and knee and hip OA, in 2 independent populations of Japanese individuals. The effect on TGFβ activity is allele specific, with the D14 allele resulting in greater inhibition than that associated with other alleles. An association of the same polymorphism with OA was later reported among patients of Greek origin with knee OA (14), but no such association was observed among female patients with hip or knee OA in a Caucasian UK population (although a weaker association was observed among male patients) (15), and no association was observed among Spanish patients of either sex (16).
Calmodulin is an intracellular protein that interacts with several proteins involved in signal transduction. Mechanical compression of articular chondrocytes is known to trigger changes in aggrecan expression, and such changes are dependent on calmodulin signaling (17). A group of Japanese investigators (18) reported a significant association between hip OA and an SNP (IVS3 −293CT) located in intron 3 of the calmodulin 1 gene (CALM1). CALM1 was expressed in cultured chondrocytes and articular cartilage, and its expression was increased in OA. Subsequent linkage disequilibrium mapping identified 5 SNPs showing significant association equivalent to that of IVS3 −293C>T. Functional analyses indicate that the alleles in the promoter in linkage disequilibrium with this variant decreased CALM1 transcription in vitro and in vivo. More recently, however, Loughlin and colleagues (19) were unable to replicate those results in a large and well-powered study of UK Caucasian women with hip OA (the Oxford study).
The cartilage oligomeric matrix protein gene (COMP) is a member of the thrombospondin gene family, which is known to be expressed more abundantly in OA cartilage than in normal cartilage (20). Prospective studies have shown that elevated serum levels of COMP are observed early in patients in whom chronic knee pain without radiographic OA progresses to radiographic disease (21). An association of serum concentrations of COMP with prevalent OA has also been reported, for COMP alone and in combination with other serum markers (21), and elevated serum levels of COMP may be a marker of rapid radiographic progression (22). Several COMP mutations produce osteochondral dysplasias (Online Mendelian Inheritance in Man, Johns Hopkins University, Baltimore, MD; online at http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=600310). Such disorders produce severe, early-onset OA and are models for common idiopathic OA.
Based on such data, Mabuchi et al (23) hypothesized that OA, as a common disorder, may be at the mild end of the phenotypic gradation produced by COMP mutations. Using 6 polymorphisms spanning the entire gene, those investigators examined the association of COMP in Japanese patients with OA of the knee and hip joints and observed no statistically significant evidence for association. Given that some genes appear to be associated in Japanese but not Caucasian individuals, we explored the possibility that there is a genetic association between COMP variants and knee OA in Caucasians.
Type II collagen is the major collagen in cartilage. Mutations in the type II collagen gene, COL2A1, have been observed in various types of chondrodysplasias. Studies performed in the early 1990s could not provide any evidence for an influence of COL2A1 variants in OA susceptibility (24). Analyses of COL2A1 performed a few years later, however, suggested an association of COL2A1 polymorphisms with hip and knee OA in subjects from the Rotterdam study (25) and in independent Japanese cohorts (26). COL2A1 is in close physical proximity to the vitamin D receptor gene (VDR); however, a group of Dutch investigators showed that both VDR and COL2A1 influence the risk of knee OA in a manner that is not attributable to linkage disequilibrium between the 2 genes (27). Other investigators failed to identify any such association in populations in the US (28) and Finland (29).
The strongest evidence for a real connection between a gene and a disease or trait should come from a systematic replication of a statistically significant association, in which any source of bias or inconsistency has been eliminated (30). After several independent groups of investigators replicate a finding, it seems reasonable to conclude with sufficient certainty that a link between a gene and a disease has been demonstrated (31). Three possible reasons accounting for the inconsistency of results are the different ethnicities of the subjects investigated, the sites of OA that were chosen, and the sex of the patients and controls. We recently reported that genetic associations with knee OA are strongly influenced by sex (32). In the current study, we assessed genetic variants in the above-mentioned 5 genes in an ethnically homogeneous cohort of patients with knee OA, analyzing men and women separately.
- Top of page
- PATIENTS AND METHODS
- AUTHOR CONTRIBUTIONS
At the level of individual SNP allele frequency (Table 1), only the comp_386 SNP was statistically significantly (P < 0.05) associated with OA in women, and the comp_5p and the col2_int SNPs were associated in men. However, an almost significant association (P < 0.053) was observed with the FRZB R200W SNP among women. When we compared haplotype frequencies between patients with knee OA and control subjects, we observed that the same FRZB haplotype (W200/G324) reported to be associated with hip OA in other studies was associated with increased risk of knee OA (OR 2.87, P < 0.04) (Table 2), although the strongest association was the protective effect of the wild-type haplotype (OR 0.70, P < 0.012). These associations were observed only among women.
Table 1. Association of individual SNPs with knee OA in study subjects, according to sex*
|Gene||Position||SNP alias||Reference SNP||SNP description||DNA change||HWE†||Minor allele frequency, %|
|OA (n = 305)||Controls (n = 299)||OR||95% CI||P||OA (n = 298)||Controls (n = 300)||OR||95% CI||P|
|ASP (chr 9)||92295895||aspn_1||rs7022562||5′-UTR||T>C||<1.0||30.0||31.5||0.93||0.73–1.19||<0.573||33.0||29.2||1.19||0.92–1.54||<0.182|
|CALM1 (chr 14)||89939666||ivs3-293||rs3213718||Intron 1||C>T||<0.89||35.8||39.8||1.19||0.94–1.50||<0.151||36.7||39.0||1.10||0.86–1.40||<0.439|
|COL2A1 (chr 12)||46654096||col2_int||rs1635560||Intron 11||C>T||<0.76||24.8||24.5||1.01||0.77–1.32||<0.930||19.6||26.5||0.68||0.51–0.89||<0.005|
|COMP (chr 19)||18758455||comp_386||Valdes et al (20)||N386D||A>G||<0.85||9.2||5.4||1.77||1.12–2.77||<0.013||5.4||5.5||0.97||0.59–1.60||<0.899|
| ||18764495||comp_5p||Mabuchi et al (23)||5′-UTR −1417||C>G||<0.59||8.8||10.1||0.86||0.58–1.27||<0.446||13.6||9.6||1.48||1.03–2.13||<0.032|
|FRZB (chr 2)||183528842||frzb_200||rs288326||R200W||C>T||<0.77||13.0||9.5||1.43||0.99–2.05||<0.053||12.7||13.0||0.98||0.69–1.39||<0.894|
Table 2. Estimated haplotype frequencies of ASPN, COL2A1, COMP, and FRZB among patients with knee OA and controls, and their association with knee OA*
|Frequency||OR||95% CI||P||Frequency||OR||95% CI||P|
|ASPN|| || || || || || || || || || || |
| aspn_1, spn_2,||TTTCC||49.7||50.0||0.99||0.79–1.24||<0.929||46.2||50.1||0.85||0.67–1.08||<0.190|
| aspn_3, spn_4,||CCCAT||24.6||28.3||0.83||0.64–1.07||<0.151||27.9||25.0||1.16||0.89–1.52||<0.277|
|COL2A1|| || || || || || || || || || || |
| col2_int, col2_1405||CC||66.0||66.1||1.00||0.79–1.26||<0.974||69.6||63.9||1.30||1.02–1.65||<0.036|
| ||TT||0.3||0.2||1.48||0.16–13.47||<0.709||0.0||0.0|| || || |
|COMP|| || || || || || || || || || || |
| comp_386, comp_5p||AC||82.1||84.5||0.84||0.62–1.14||<0.258||81.1||84.9||0.76||0.56–1.03||<0.080|
|FRZB|| || || || || || || || || || || |
| frzb_200, frzb_324||CC||79.4||84.6||0.70||0.52–0.95||<0.012||83.3||83.7||0.98||0.71–1.35||<0.953|
We also observed that haplotypes in COMP were associated with knee OA, but that the specific haplotypes involved were different in men and women. The COL2A1 haplotype was also significantly associated with knee OA but only in men, with no association in women. We did not find evidence that the CALM1 polymorphism affects the risk of OA, although the frequency of the minor allele was modestly increased in women with OA compared with controls.
None of the individual SNPs typed for ASPN was, by itself, associated with knee OA. However, the frequency of a 5-SNP haplotype (CTTAT) was modestly increased in both male patients and female patients compared with controls, but the difference was not statistically significant in patients of either sex. When the data for both sexes were combined, the haplotype frequency in patients (5.2%) was significantly higher than that in controls (3.5%) (OR 1.53, 95% CI 1.02–2.30). An analysis of pairwise linkage disequilibrium between ASPN 5-SNP haplotypes and the ASPN aspartic acid repeat alleles revealed that specific SNP haplotypes were commonly associated with the 3 most common aspartic acid repeat alleles (Figure 1). These data indicate that although not all of the information on allele D14 was captured by the 5-SNP haplotypes, sufficient information on alleles D12 and D13 was captured by the 5 SNPs (r2 > 0.77).
We summarized the data from the current study, compared them with those from previous association studies, and carried out meta-analyses for all genes except COL2A1 (Table 3). The strongest evidence from the meta-analysis was for the FRZB G324 allele in women (P < 0.0003), followed by the FRZB W200 allele in women (P < 0.004) (Table 3). The meta-analysis also indicated that neither of these 2 variants influences the risk of OA in men. Combining the data for ASPN genetic variants in Caucasians and Japanese populations resulted in a significant association for the D14 allele, although data sets for Caucasians alone provided no evidence for this (Table 3). However, the meta-analysis of 3 data sets for Caucasians indicated that D13—the protective allele in Japanese individuals—is statistically significantly associated with a decreased risk of knee OA in Caucasian individuals. Combining data for Caucasians and Japanese resulted in a nearly significant association between CALM1 and the TT genotype, but no evidence for an association was seen in Caucasians only. Finally, combining the current data with published data for Japanese populations provided no evidence for an association between COMP and knee OA.
Table 3. Previous associations, summary of current results, and meta-analysis results*
|Gene||Ref.||Population||Trait||Replications (refs.)||Known/hypothesized function in OA||Observed result in current study||Meta-analysis results|
|ASPN||13||Japanese||Knee, hip OA||Negative (15, 16); positive on a different allele (14)||Cartilage extracellular protein that regulates the activity of TGFβ||Weak association of ASPN haplotype in LD with D12 in both sexes||D14, Cauc + Jap; OR 1.31 (95% CI 1.10–1.56), P < 0.002† D14, Cauc only; OR 1.14 (95% CI 0.94–1.40), P NS D13, Cauc only; OR 0.85 (95% CI 0.74–0.97) P < 0.02|
|FRZB||8||UK||Hip OA||Positive (9, 10)||Modulator of chondrocyte maturation||Association only in women||W200, F only; OR 1.25 (95% CI 1.07–1.47), P < 0.004‡ W200, M only; OR 0.95 (95% CI 0.75–1.19), P NS W200, M + F; OR 1.04 (95% CI 0.91–1.19), P NS|
| || || || || || || || G324, F only; OR 1.38 (95% CI 1.16–1.65), P < 0.0003|
| || || || || || || || G324, M only; OR 0.82 (95% CI 0.61–1.11), P NS|
| || || || || || || || G324, M + F; OR 1.21 (95% CI 1.02–1.42), P < 0.022|
|COMP||23||Japan||No association with hip/knee OA||None||Cartilage matrix macromolecule||Association in both sexes, but different haplotypes||−1417 G; OR 1.05 (95% CI 0.86–1.29), P NS§|
|COL2A1||25||Netherlands||Knee, hip OA||Negative (24, 27, 36,); positive (26)||Major cartilage collagen, structural cartilage component||Associated only in men||NA|
|CALM1||18||Japan||Hip OA||Negative (19)||Intracellular protein, interacts with proteins involved in signal transduction||No association observed||TT, Cauc + Jap; OR 1.15 (95% CI 0.99–1.33), P < 0.055¶ TT, Cauc only; OR 1.02 (95% CI 0.88–1.20), P NS|
- Top of page
- PATIENTS AND METHODS
- AUTHOR CONTRIBUTIONS
Our data confirm striking sex-related differences in certain genes, in particular FRZB, and are supportive of previously published results regarding hip OA in Caucasian populations, namely, that the FRZB T/G haplotype is involved in the pathogenesis of OA, but only in women. However, the present study is, to our knowledge, the first to show a genetic association with knee OA. We must note that some of the subjects used in the current study (the 185 female control subjects from Oxford) are shared between this study and the original study by Loughlin et al (8). For this reason, the 2 studies are not totally independent. However, the trends observed for the combined set of control subjects were the same as those observed when only the Nottingham control subjects were used. For example, when only the Nottingham control subjects were considered, the FRZB R200W polymorphism had an OR of 1.57; when the Oxford control subjects were included the OR was 1.31.
Because the biologic rationale for involvement of ASPN in OA susceptibility is very strong and is based solely on the functional properties of asporin, Kizawa and coworkers (13) decided to test ASPN for association with OA. They not only observed a genetic association with an aspartic acid repeat but also demonstrated that it is abundantly expressed in OA articular cartilage and found that asporin inhibits the expression of the genes encoding aggrecan and type II collagen. Three studies in Caucasian populations were unable to demonstrate an association with allele D14, the risk allele in the Japanese study, and, according to our own data, the 5-SNP haplotype in linkage disequilibrium with this allele is not associated with knee OA, although our study did not capture sufficient genetic variation to fully mark this allele.
The haplotype that is modestly increased in patients with knee OA relative to controls is in linkage disequilibrium with allele D12, an allele that was not implicated in OA risk in any of the previous studies. However, evidence from combined data for 3 independent Caucasian populations from Greece, Spain, and the UK (14–16) indicated that the D13 allele is indeed associated with a reduced risk of knee OA. According to our own data, the haplotype in linkage disequilibrium with the D13 allele (TTTCC) was less frequent among patients with knee OA than among controls (Table 2), although the difference was not statistically significant. Thus, although none of the studies of Caucasians has provided evidence of an association between the D14 allele and an increased risk of OA, the combined data for Europeans point toward a decreased risk of knee OA in carriers of the D13 allele and, taken together, would confirm a role for ASPN in susceptibility to knee OA not only in Japanese individuals but also in Caucasians.
Unlike the situation with ASPN, in which we covered a vast proportion of variation within the gene, we tested only one SNP for CALM1, and we were unable to detect any association with knee OA for this specific SNP. Because we tested no other polymorphisms within CALM1, we cannot exclude the possibility that other variants in weak or no linkage disequilibrium with the current SNP could influence the genetic risk of knee OA. However, another UK-based study (19) was unable to detect an association between hip OA and a CALM1 SNP that is in complete linkage disequilibrium with the SNP we studied here. This could suggest that whatever role this variant within CALM1 plays in genetic susceptibility to OA in Caucasians, it is likely to be a modest one.
Unlike a previous Japanese study, in the present study we observed that COMP contributed to the risk of knee OA, albeit in a different manner in men compared with women. The association we observed was not particularly strong but was consistent with expression data comparing normal and OA-affected cartilage (20), the fact that serum levels of COMP are increased in OA (22), and the fact that COMP levels are heritable (34). A meta-analysis including both sets of data, however, showed no evidence of association between knee OA and COMP. Further research is needed to clarify the role of genetic variation at this gene in susceptibility to OA in Caucasians.
Finally, COL2A1, which has been shown to be associated with OA in some studies (e.g., Rotterdam) (25) but not in others (e.g., Framingham) (28), appeared to be associated with OA only in men. Because we investigated only 2 genetic variants at this gene, we cannot exclude the possibility that other polymorphisms might also be involved in women in this cohort. Interestingly, one of the earlier studies of the risk of knee OA and COL2A1 indicated that different VNTR alleles were associated in men compared with women (27).
Apart from the facts that it was not feasible to cover all genetic variation in the genes analyzed (which would be possible only through resequencing) and that only common variants were studied, there are other limitations to the present study. Only limited data were available for control subjects, which did not allow us to test possible confounders such as obesity. However, previous modeling studies showed no genetic correlation of knee OA with obesity (35), making it unlikely that we had merely confirmed obesity genes. It is also possible that the use of different genotyping methodologies can result in lower call rates for some assays, and that this could be the source of inconsistencies across studies. Such error, however, is most likely to be unbiased, and its effect would be a small reduction in power (corresponding at most to a 6% reduction in sample size). Multiple testing was not a problem, because all of the tests were considered a priori, with the exception of the test for ASPN, in which we did not test the exact same variants as those tested in previous studies.
Another potential source of error is that haplotype comparisons derived from unphased data carry the possibility of obtaining a larger Type I error than the nominal one (36). However, because we analyzed our data with those from several published studies, for the most part as individual polymorphisms, this is unlikely to have biased our conclusions. A final confounding factor could be population stratification; however, all of the study subjects were ethnically matched (Caucasians from the UK), which makes this an unlikely possibility.
In conclusion, our results highlight the strong reproducibility of several important candidate gene associations with OA and the fact that many of these associations are strongly dependent on sex and ethnicity and are often probably site specific. OA is now one of the few common diseases in which a large number of candidate genes have been consistently and independently replicated. Additional research to exploit the combined effects of these and other candidate genes and to determine how environmental factors modify the genetic risk will greatly help in understanding the etiology of this complex disease and forming the basis of clinical susceptibility tests.
- Top of page
- PATIENTS AND METHODS
- AUTHOR CONTRIBUTIONS
Dr. Spector had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Study design. Drs. Valdes, Loughlin, Doherty, and Spector.
Acquisition of data. Mr. van Oene, Dr. Chapman, and Ms Surdulescu.
Analysis and interpretation of data. Drs. Valdes, Loughlin, and Spector.
Manuscript preparation. Drs. Valdes, Loughlin, and Spector.
Statistical analysis. Dr. Valdes.
Patient enrollment. Dr. Doherty.